Revised forecast
Fiscal year ending March 2026 · Full yearThe temporary reduction in monthly fees during the first half in response to deteriorating profitability at some of the medical institutions receiving support, and the decline following the concentration of M&A support fees from large projects in the first quarter of the previous fiscal year.
| Item | Details |
|---|---|
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Previous-period results | Revenue ¥7,945 million, operating profit ¥2,151 million, ordinary profit ¥2,002 million, net income ¥1,426 million, earnings per share ¥48.63 |
| Reason for the revision | The temporary reduction in monthly fees during the first half in response to deteriorating profitability at some of the medical institutions receiving support, and the decline following the concentration of M&A support fees from large projects in the first quarter of the previous fiscal year. |
| Consolidated / non-consolidated | Non-consolidated |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The decline in revenue was due to the temporary reduction in monthly fees during the first half in response to deteriorating profitability at some of the medical institutions receiving support, as well as the absence of the concentration of M&A support fees from large projects in the first quarter of the previous fiscal year.